Trials / Completed
CompletedNCT03789656
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
An Open Label Exploratory Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients With Acromegaly Treated With Somatostatin Analogue Based Treatment Regimens (ACROBAT Edge)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Crinetics Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paltusotine | Paltusotine, capsules, once daily by mouth |
Timeline
- Start date
- 2019-03-12
- Primary completion
- 2020-08-03
- Completion
- 2020-08-31
- First posted
- 2018-12-28
- Last updated
- 2025-02-17
- Results posted
- 2025-02-17
Locations
26 sites across 12 countries: United States, Brazil, Germany, Greece, Hungary, Italy, New Zealand, Poland, Romania, Serbia, Slovakia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03789656. Inclusion in this directory is not an endorsement.